MCID: SBS004
MIFTS: 45

Substance Dependence

Categories: Mental diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Substance Dependence

MalaCards integrated aliases for Substance Dependence:

Name: Substance Dependence 11 53 14 71 75

Classifications:



External Ids:

Disease Ontology 11 DOID:9973
NCIt 49 C35458
SNOMED-CT 68 255338002
UMLS 71 C0038580 C0439857

Summaries for Substance Dependence

Disease Ontology: 11 A substance-related disorder that involves the continued use of alcohol or other drugs despite problems related to use of the substance.

MalaCards based summary: Substance Dependence is related to drug dependence and alcohol dependence. An important gene associated with Substance Dependence is OPRM1 (Opioid Receptor Mu 1), and among its related pathways/superpathways are Signal Transduction and Class A/1 (Rhodopsin-like receptors). The drugs Dopamine and Paroxetine have been mentioned in the context of this disorder. Affiliated tissues include brain, prefrontal cortex and cortex, and related phenotypes are homeostasis/metabolism and nervous system

Wikipedia: 75 Substance dependence, also known as drug dependence, is a biopsychological situation whereby an... more...

Related Diseases for Substance Dependence

Diseases related to Substance Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 159)
# Related Disease Score Top Affiliating Genes
1 drug dependence 32.2 SLC6A4 SLC6A3 OPRM1 OPRD1 GABRA2 DRD4
2 alcohol dependence 32.0 TPH1 SLC6A4 SLC6A3 OPRM1 OPRD1 H2AC18
3 tobacco addiction 31.9 TPH1 SLC6A4 SLC6A3 OPRM1 H2AC18 GABRA2
4 alcohol use disorder 31.5 SLC6A4 SLC6A3 OPRM1 H2AC18 GABRA2 DRD4
5 personality disorder 31.4 TPH1 SLC6A4 SLC6A3 DRD4 DRD3 DRD2
6 post-traumatic stress disorder 31.4 SLC6A4 SLC6A3 H2AC18 DRD2 CNR1
7 smoking as a quantitative trait locus 3 31.3 CHRNA5 CHRNA3
8 substance abuse 31.3 SLC6A4 SLC6A3 OPRM1 H2AC18 GABRA2 DRD4
9 opiate dependence 31.3 SLC6A4 SLC6A3 OPRM1 OPRD1 DRD4 DRD3
10 borderline personality disorder 31.2 TPH1 SLC6A4 SLC6A3 DRD2
11 bipolar disorder 31.2 TPH1 SLC6A4 SLC6A3 OPRM1 GABRA2 DRD5
12 antisocial personality disorder 31.2 SLC6A4 SLC6A3 GABRA2 DRD4 DRD2 ANKK1
13 conduct disorder 31.1 TPH1 SLC6A4 SLC6A3 GABRA2 DRD5 DRD4
14 bulimia nervosa 31.1 SLC6A4 SLC6A3 DRD4 DRD2 CNR1
15 polysubstance abuse 31.1 DRD3 DRD2 CNR1
16 cannabis dependence 31.1 GABRA2 DRD2 CNR1 ANKK1
17 major depressive disorder 31.0 TPH1 SLC6A4 SLC6A3 OPRM1 DRD5 DRD4
18 anxiety 31.0 TPH1 SLC6A4 SLC6A3 OPRM1 GABRA2 DRD4
19 psychotic disorder 31.0 TPH1 SLC6A4 SLC6A3 OPRM1 H2AC18 DRD5
20 panic disorder 30.9 TPH1 SLC6A4 SLC6A3 DRD4 DRD3 DRD2
21 cocaine dependence 30.9 SLC6A4 SLC6A3 OPRM1 OPRD1 GABRA2 DRD3
22 mood disorder 30.9 TPH1 SLC6A4 SLC6A3 H2AC18 DRD4 DRD3
23 generalized anxiety disorder 30.9 TPH1 SLC6A4 H2AC18 DRD2
24 withdrawal disorder 30.8 SLC6A4 SLC6A3 OPRM1 DRD2 CNR1
25 attention deficit-hyperactivity disorder 30.8 TPH1 SLC6A4 SLC6A3 OPRM1 H2AC18 GABRA2
26 eating disorder 30.8 SLC6A4 SLC6A3 OPRM1 H2AC18 DRD2 CNR1
27 heroin dependence 30.8 SLC6A4 SLC6A3 OPRM1 OPRD1 DRD4 DRD3
28 chronic pain 30.8 OPRM1 CNR1
29 disease of mental health 30.6 SLC6A4 SLC6A3 OPRM1 H2AC18 DRD4 DRD3
30 social phobia 30.6 SLC6A4 SLC6A3 DRD2
31 pathological gambling 30.6 SLC6A4 SLC6A3 OPRM1 DRD5 DRD4 DRD3
32 alexithymia 30.6 SLC6A4 H2AC18 DRD2 ANKK1
33 hallucinogen dependence 30.6 GABRA2 DRD2 CNR1 ANKK1
34 sleep disorder 30.6 SLC6A4 SLC6A3 H2AC18
35 cannabis abuse 30.6 SLC6A4 DRD4 DRD2 CNR1 ANKK1
36 anorexia nervosa 30.6 TPH1 SLC6A4 DRD4 DRD2 CNR1
37 schizophrenia 30.4 TPH1 SLC6A4 SLC6A3 OPRM1 GABRA2 DRD5
38 dysthymic disorder 30.4 SLC6A4 SLC6A3 DRD4
39 phobic disorder 30.4 SLC6A4 SLC6A3 H2AC18 DRD2
40 schizoaffective disorder 30.4 SLC6A4 DRD4 DRD3 DRD2
41 endogenous depression 30.4 TPH1 SLC6A4 SLC6A3 H2AC18 DRD2
42 drug psychosis 30.4 SLC6A3 DRD2
43 alzheimer disease, familial, 1 30.4 TPH1 SLC6A4 SLC6A3 OPRM1 H2AC18 DRD4
44 obsessive-compulsive disorder 30.3 TPH1 SLC6A4 SLC6A3 DRD4 DRD3 DRD2
45 melancholia 30.3 TPH1 SLC6A4
46 oppositional defiant disorder 30.2 SLC6A4 SLC6A3 GABRA2 DRD5 DRD4 DRD3
47 sexual health disorder 30.1 SLC6A4 H2AC18
48 hyperphenylalaninemia, bh4-deficient, a 10.5
49 opioid abuse 10.5 OPRM1 OPRD1 DRD2
50 cyclothymic disorder 10.5 SLC6A4 DRD4 DRD2

Graphical network of the top 20 diseases related to Substance Dependence:



Diseases related to Substance Dependence

Symptoms & Phenotypes for Substance Dependence

GenomeRNAi Phenotypes related to Substance Dependence according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.21 ADH1A ADH1B ADH1C ALDH2 ANKK1 CHRNA3
2 no effect GR00402-S-2 10.21 ADH1A ADH1B ADH1C ALDH2 ANKK1 CHRNA3

MGI Mouse Phenotypes related to Substance Dependence:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.22 ADH1A ADH1B ADH1C ALDH2 CHRNA3 CHRNB4
2 nervous system MP:0003631 10.21 ALDH2 CHRNA3 CHRNA5 CHRNB4 CNR1 DRD2
3 growth/size/body region MP:0005378 10.1 ADH1A ADH1B ADH1C ALDH2 CHRNA3 CHRNB4
4 behavior/neurological MP:0005386 10.03 ALDH2 CHRNA3 CHRNA5 CHRNB4 CNR1 DRD2
5 mortality/aging MP:0010768 9.8 ADH1A ADH1B ADH1C ALDH2 CHRNA3 CHRNB4
6 integument MP:0010771 9.36 ALDH2 CHRNA5 CHRNB4 CNR1 DRD2 GABRA2

Drugs & Therapeutics for Substance Dependence

Drugs for Substance Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 57)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
2
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
3
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7, 53152-21-9 644073 40400
4
Nicotine Approved Phase 4 54-11-5 942 89594
5
Bupropion Approved Phase 4 31677-93-7, 34841-39-9, 34911-55-2 444
6
Diamorphine Approved, Illicit, Investigational Phase 4 561-27-3 5462328
7
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
8
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
9
Cocaine Approved, Illicit Phase 4 50-36-2 446220 5760
10
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
11 Dopamine Uptake Inhibitors Phase 4
12 Dopamine Agents Phase 4
13 Neurotransmitter Agents Phase 4
14
Lisdexamfetamine Dimesylate Phase 4
15 Psychotropic Drugs Phase 4
16 Antidepressive Agents Phase 4
17 Serotonin Uptake Inhibitors Phase 4
18 Cytochrome P-450 Enzyme Inhibitors Phase 4
19 Analgesics Phase 4
20 Narcotics Phase 4
21 Buprenorphine, Naloxone Drug Combination Phase 4
22 Narcotic Antagonists Phase 4
23 Antipsychotic Agents Phase 4
24 Dopamine Antagonists Phase 4
25
Quetiapine Fumarate Phase 4 111974-72-2
26 Anticonvulsants Phase 4
27
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
28
Cathine Approved, Experimental, Illicit, Vet_approved, Withdrawn Phase 3 14838-15-4, 492-39-7 131954576 4786 26934
29
Methadone Approved Phase 3 76-99-3, 1095-90-5 4095
30
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
31 Respiratory System Agents Phase 3
32 Antitussive Agents Phase 3
33 Chlorpheniramine, phenylpropanolamine drug combination Phase 3
34
Metamfetamine Approved, Illicit, Withdrawn Phase 2 537-46-2 10836
35
Modafinil Approved, Investigational Phase 2 68693-11-8 4236
36
Propranolol Approved, Investigational Phase 2 318-98-9, 525-66-6 62882 4946
37 Adrenergic beta-Antagonists Phase 2
38 Adrenergic Antagonists Phase 2
39 Adrenergic Agents Phase 2
40 Anti-Arrhythmia Agents Phase 2
41 Antihypertensive Agents Phase 2
42 Vasodilator Agents Phase 2
43
Caffeine Approved Phase 1 58-08-2 2519
44 Naxagolide Phase 1 10060538
45 Phosphodiesterase Inhibitors Phase 1
46 Pharmaceutical Solutions Phase 1
47 Anti-Infective Agents Phase 1
48 Anti-Infective Agents, Local Phase 1
49
Dronabinol Approved, Illicit 1972-08-3 16078
50
Varenicline Approved, Investigational 249296-44-4 5310966

Interventional clinical trials:

(show top 50) (show all 59)
# Name Status NCT ID Phase Drugs
1 Pilot Study of Vyvanse™ (Lisdexamfetamine Dimesylate) in Adolescents (Ages 11-15) With ADHD and an Older Sibling With ADHD and Substance Dependence Completed NCT00573534 Phase 4 Vyvanse
2 Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence Completed NCT00330239 Phase 4 Paroxetine CR
3 Randomized Clinical Trial Comparing a Medication, i.e., Sustained-Release Bupropion (Zyban®) With an Ultrashort (1 1/2 d) Manual-Based Psychotherapeutic Intervention, Psychodynamic Model Training® Completed NCT00484692 Phase 4 sustained-release bupropion (Zyban(R))
4 A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users Completed NCT00604188 Phase 4 Suboxone (SCH 000484);Subutex (SCH 028444)
5 Seroquel (Quetiapine) Therapy for Schizophrenia and Schizoaffective Disorders and Comorbid Cocaine and/or Amphetamine Abuse/Dependence: A Comparative Study With Risperidone Completed NCT00208143 Phase 4 Quetiapine;Risperidone
6 Depakote ER Therapy for Mania Comorbid With Substance Abuse Completed NCT00208195 Phase 4 Divalproex ER
7 Improving Outcomes in Psychosis Associated With Substance Use Using Aripiprazole Withdrawn NCT01155544 Phase 4
8 Initialization of Methadone in Primary Care; a Randomized Intervention Research for Preventing HCV Transmission Practices. ANRS Methaville Completed NCT00657397 Phase 3 Methadone
9 Adolescent Outpatient and Continuing Care Study Completed NCT01381133 Phase 3
10 A Dose Ranging Study of Modafinil for Methamphetamine Dependence Unknown status NCT00630097 Phase 2 modafinil
11 A Stage 1 Study of Community Reinforcement and Family Training for Treatment Drug Abuse Treatment Retention/HIV Risk Reduction Unknown status NCT00609089 Phase 1, Phase 2
12 Distress Tolerance Treatment for Substance Users Unknown status NCT01741415 Phase 2
13 Group IPT for Women Prisoners With Comorbid Substance Use and Depression Completed NCT00606996 Phase 2
14 Motivating Treatment Seeking and Behavior Change by Untreated Military Personnel Abusing Alcohol or Drugs Completed NCT01128140 Phase 2
15 Reinforcement of Abstinence and Attendance in Substance Abuse Treatment Completed NCT00288886 Phase 2
16 Memory Reconsolidation Blockade for Treating Drug Addiction: a Feasibility Study Completed NCT01634347 Phase 2 Propranolol and memory reactivation;Placebo and memory reactivation
17 Cognitive Remediation and Work Therapy in the Initial Phase of Substance Abuse Treatment Completed NCT01410110 Phase 2
18 A Study to Investigate the Effects of GSK598809 in Newly Abstinent Nicotine-dependent Subjects. Withdrawn NCT00793468 Phase 2 GSK598809;Nicotine Replacement Transdermal Patch;Placebo
19 An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain Dopamine D3 Receptor Occupancy, Pharmacokinetics and Safety of Single Oral Doses of GSK618334, Using 11C-PHNO as PET Ligand. Completed NCT00814957 Phase 1 GSK618334
20 A Placebo-controlled, Single-blind, Randomised, Human Volunteer Study Investigating the Tolerability and Pharmacokinetics of Escalating Single Oral Doses (75mg and Above) of GSK598809 in Otherwise Healthy Smokers Completed NCT00728052 Phase 1 GSK598809;Placebo
21 An Open Label, Randomised, Single Dose, Three-way Crossover Study to Investigate the Relative Bioavailability of a 100mg Capsule Compared to Four 25mg GSK598809 Capsules and the Effect of Food on the Pharmacokinetics of the 100mg Capsule in Healthy Male and Female Volunteers. Completed NCT00728897 Phase 1 GSK598809 new formulation;GSK598809 old formulation
22 A First Time in Human, Blinded, Randomised, Placebo-Controlled, Two-cohort Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single Oral Escalating Doses of GSK618334 in Healthy Male Volunteers Completed NCT00513279 Phase 1 GSK618334;GSK618334 matching placebo tablets
23 A Placebo-controlled, Single-blind, Randomised, Human Volunteer Study Investigating the Tolerability and Pharmacokinetics of Escalating Single Oral Doses of GSK598809 in Smokers Completed NCT00437840 Phase 1 GSK598809;Placebo
24 A Placebo Controlled, Single Blind, Randomised Study Investigating the Safety, Tolerability and Pharmacokinetics of Repeated Oral Doses of GSK598809 in Healthy Male and Female Volunteers for 28 Days. Completed NCT00437632 Phase 1 GSK598809;Placebo;Caffeine
25 A Single-blind, Randomized, Placebo Controlled, Two-period Crossover fMRI Study to Investigate the Effects of the D3 Antagonist GSK598809 on Neural and Behavioural Responses to Food Reward and Reinforcement After a Single Oral Dose of GSK598809 in Overweight and Obese Subjects. Completed NCT01039454 Phase 1 GSK598809 Capsules;GSK598809 Placebo Capsules
26 A Randomized, Double-bind, Placebo Controlled, Two-way Cross-over Study to Assess the Effects of a Single Dose of GSK598809, a Selective DRD3 Antagonist, in Modulating Nicotine Reward Completed NCT00605241 Phase 1 GSK598809
27 A Placebo-controlled, Single Blind, Randomized Two Part Study Toinvestigate the Tolerability, Pharmacokinetics, and brainDopamine D3 Receptor Occupancy of Increasing Repeat Doses ofGSK618334 for up to 21 Days in Healthy Volunteers. Completed NCT01036061 Phase 1 GSK618334 Low Dose;GSK618334 PET subjects;GSK618334 Medium Dose;GSK618334 High Dose
28 Assessment and Treatment of Caffeine Dependence Completed NCT00338195 Phase 1
29 A Study to Investigate Potential Interactions Between GSK598809 and Ethanol in Healthy Subjects Completed NCT00887367 Phase 1 GSK598809
30 A Placebo-controlled, Single-blind, Cross-over, Randomised, fMRI Study Comparing Cue-induced Brain Activation Patterns After a Single Oral Dose of GSK598809 or Placebo in Abstinent Alcoholic Subjects Withdrawn NCT00908206 Phase 1 GSK598809
31 Study on the Effectiveness of "Treatment Regulation Mode" Based on Neuromodulation and Electronic Follow-up to Reduce Relapse Behavior in Patients With Substance Dependence Unknown status NCT04139148
32 Satisfaction With Care and Quality of Life in Subjects With Substance Dependence Unknown status NCT02894476
33 Addiction and Substance Dependence in Adolescence - Neurobiological Pathomechanisms and Treatment Evaluation Unknown status NCT03444974
34 Effects of Intensive Behavioral Training Program on Impulsivity and Inhibitory Control in Smokers Unknown status NCT01314378
35 Motivational Therapy for Substance Users With Depression Unknown status NCT01189799
36 Randomized Controlled Trial of a Novel Cognitive-Behavioral Treatment for Posttraumatic Stress and Substance Dependence Completed NCT02461732
37 Addressing Alcohol/HIV Consequences in Substance Dependence - Boston ARCH Cohort Completed NCT01740115
38 A Randomized Trial of Concurrent Treatment for PTSD and Substance Dependence Completed NCT01365247
39 Efficacy of Cognitive Bias Modification in Residential Treatment for Addiction Completed NCT03000699
40 Stress, Distress Intolerance, and Drug Dependence Completed NCT00430482
41 Online Cognitive Behavioural Therapy for Addiction: Efficacy and Cost-Effectiveness in a Pragmatic Clinical Trial Completed NCT03767907
42 Family Engagement, Cross-System Linkage to Substance Use Treatment for Juvenile Probationers -- Phase 3 Completed NCT03048552
43 Improving Substance Abuse Treatment Aftercare Adherence and Outcome Completed NCT00057187
44 Characterizing Alpha5 Nicotinic Receptors in Alcohol and Nicotine Dependence Completed NCT01011907 varenicline;placebo
45 Behavioral Treatment of Drug Abuse in SPMI Patients Completed NCT00295139
46 Modifying Group Therapy for Bipolar Abusers Completed NCT00227838
47 Intervention Targeting Substance Using Older Adults With HIV Completed NCT01305629
48 fMRI Study of a Dual Process Treatment Protocol With Substance Dependent Adults Completed NCT01320748
49 Evaluation of Impulsivity on Cocaine and Crack Addicts Completed NCT01550887
50 Using Telehealth to Expand Treatment Access for Veterans With Opioid Use Disorder (CDA 18-008) Recruiting NCT05348317

Search NIH Clinical Center for Substance Dependence

Genetic Tests for Substance Dependence

Anatomical Context for Substance Dependence

Organs/tissues related to Substance Dependence:

MalaCards : Brain, Prefrontal Cortex, Cortex, Amygdala, Spinal Cord, Liver, Eye

Publications for Substance Dependence

Articles related to Substance Dependence:

(show top 50) (show all 2361)
# Title Authors PMID Year
1
Gender effect on association between DRD2 polymorphism and substance dependence in a Spanish sample. 53 62
19217722 2009
2
Haplotypic variants in DRD2, ANKK1, TTC12, and NCAM1 are associated with comorbid alcohol and drug dependence. 53 62
18828801 2008
3
CNR1 variation modulates risk for drug and alcohol dependence. 53 62
17509535 2007
4
Interaction between childhood trauma and serotonin transporter gene variation in suicide. 53 62
17356577 2007
5
Haplotype spanning TTC12 and ANKK1, flanked by the DRD2 and NCAM1 loci, is strongly associated to nicotine dependence in two distinct American populations. 53 62
17085484 2006
6
Association study of the CNR1 gene exon 3 alternative promoter region polymorphisms and substance dependence. 53 62
16741937 2006
7
Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis. 53 62
16387451 2006
8
Association between two mu-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence. 53 62
16476706 2006
9
A simple nonparametric multipoint procedure to test for linkage through mothers or fathers as well as imprinting effects in the presence of linkage. 53 62
16451620 2005
10
Combined effect of promoter polymorphisms in the dopamine D4 receptor and the serotonin transporter genes in heroin dependence. 53 62
16167465 2005
11
A genetic association study of the mu opioid receptor and severe opioid dependence. 53 62
12960749 2003
12
Haplotypes at the OPRM1 locus are associated with susceptibility to substance dependence in European-Americans. 53 62
12815747 2003
13
No association for D2 and D4 dopamine receptor polymorphisms and methamphetamine abuse in Chinese males. 53 62
11901357 2002
14
A functional polymorphism within the mu-opioid receptor gene and risk for abuse of alcohol and other substances. 53 62
11840318 2002
15
The D3 dopamine receptor and substance dependence. 53 62
11681590 2001
16
Family-based study of DRD2 alleles in alcohol and drug dependence. 53 62
11054774 2000
17
Antisociality, substance dependence, and the DRD5 gene: a preliminary study. 53 62
11054773 2000
18
Variant detection at the delta opioid receptor (OPRD1) locus and population genetics of a novel variant affecting protein sequence. 53 62
10982041 2000
19
No association between D2 dopamine receptor (DRD2) alleles or haplotypes and cocaine dependence or severity of cocaine dependence in European- and African-Americans. 53 62
10023512 1999
20
Serotonin transporter protein gene polymorphism and personality measures in African American and European American subjects. 53 62
9766763 1998
21
Population studies of polymorphisms at loci of neuropsychiatric interest (tryptophan hydroxylase (TPH), dopamine transporter protein (SLC6A3), D3 dopamine receptor (DRD3), apolipoprotein E (APOE), mu opioid receptor (OPRM1), and ciliary neurotrophic factor (CNTF)). 53 62
9790747 1998
22
Association of alcohol or other drug dependence with alleles of the mu opioid receptor gene (OPRM1). 53 62
9756053 1998
23
An association between a microsatellite polymorphism at the DRD5 gene and the liability to substance abuse: pilot study. 53 62
9583233 1998
24
Mu opioid receptor gene variants: lack of association with alcohol dependence. 53 62
9399694 1997
25
Hospital policies can create barriers to good management of opioid withdrawal. 62
36460314 2022
26
All in a scent - naphthalene dependence confined to pregnancy: a case report. 62
36403047 2022
27
[Burnout and dependence among medical personnel timeless and during the COVID-19 pandemic, using surgery and anesthesia as examples]. 62
35737018 2022
28
Augmenting trauma-focused psychotherapy for post-traumatic stress disorder with brief aerobic exercise in Australia: a randomised clinical trial. 62
36436532 2022
29
Cannabis use, abuse and dependence during the COVID-19 pandemic: a scoping review. 62
36346483 2022
30
Personal Social Networks and Relapses in Women With Substance Dependence: Application of the Theory of Planned Behavior. 62
36327959 2022
31
Clinical, environmental, and genetic risk factors for substance use disorders: characterizing combined effects across multiple cohorts. 62
36195638 2022
32
Preparedness for healthy ageing and polysubstance use in long-term cannabis users: a population-representative longitudinal study. 62
36202130 2022
33
Predictors of Frailty in the Elderly Population: A Cross-Sectional Study at a Tertiary Care Center. 62
36415357 2022
34
Demographic and Selection Histories of Populations Across the Sahel/Savannah Belt. 62
36173804 2022
35
Associations between psychosocial risk factors, and changes in substance dependence and psychosocial functioning, during engagement with digital cognitive behavioral therapy for methamphetamine use: use of 'Breaking Free from Substance Abuse' by incarcerated people during the COVID-19 pandemic. 62
36070026 2022
36
Pairwise genetic meta-analyses between schizophrenia and substance dependence phenotypes reveals novel association signals with pharmacological significance. 62
36151087 2022
37
Prevalence and association of comorbid substance dependence on the course and outcome of bipolar disorder: Findings from the bipolar disorder course and outcome study from India (BiD-CoIN study). 62
36458086 2022
38
Effects of Long-Term Administration of Q808 on Hippocampal Transcriptome in Healthy Rats. 62
35831127 2022
39
[Analysis of effective connectivity in default mode network in male long-term smokers based on dynamic causal modeling]. 62
36124348 2022
40
What Prevention and Treatment of Substance Dependence Can Tell Us About Addressing Violent Extremism. 62
36238006 2022
41
Predictors of Gaming Disorder or Protective from It, in a French Sample: A Symptomatic Approach to Self-Regulation and Pursued Rewards, Providing Insights for Clinical Practice. 62
35954855 2022
42
Sex-dependent Effects of the Drugs of Abuse Amphetamine and the Smart Drug 3,4-Methylenedioxypyrovalerone on Fear Memory Generalization in Rats. 62
34968670 2022
43
The effect of environment on cross-sensitization between methylphenidate and amphetamine in female rats. 62
35594929 2022
44
Distress tolerance: prospective associations with cognitive-behavioral therapy outcomes in adults with posttraumatic stress and substance use disorders. 62
34994673 2022
45
Psychiatric morbidity in family members of alcohol dependence patients. 62
36419709 2022
46
Levels of impulsivity in individuals with cannabis use disorder. 62
35500250 2022
47
Associations between classic psychedelics and nicotine dependence in a nationally representative sample. 62
35732796 2022
48
Presentation and Outcomes of Otolaryngologic Surgeries in Patients With Mental Illness History. 62
35766624 2022
49
Catechol-O-methyltransferase activity in individuals with substance use disorders: a case control study. 62
35729517 2022
50
Bridge Nodes between Personality Traits and Alcohol-Use Disorder Criteria: The Relevance of Externalizing Traits of Risk Taking, Callousness, and Irresponsibility. 62
35743541 2022

Variations for Substance Dependence

Expression for Substance Dependence

Search GEO for disease gene expression data for Substance Dependence.

Pathways for Substance Dependence

Pathways related to Substance Dependence according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1 13.52 TPH1 OPRM1 OPRD1 H2AC18 DRD5 DRD4
2
Show member pathways
13.2 OPRM1 OPRD1 DRD5 DRD4 DRD3 DRD2
3
Show member pathways
12.95 SLC6A4 SLC6A3 GABRA2 CHRNB4 CHRNA5 CHRNA3
4 12.17 DRD5 DRD4 DRD3 DRD2
5
Show member pathways
11.77 DRD5 DRD4 DRD3 DRD2
6 11.73 DRD4 DRD3 CNR1
7
Show member pathways
11.52 CHRNB4 CHRNA5 CHRNA3
8
Show member pathways
11.19 DRD4 DRD3 DRD2 CHRNA5 CHRNA3
9 11.05 ALDH2 ADH1C ADH1B ADH1A
10
Show member pathways
10.98 ALDH2 SLC6A3 SLC6A4
11
Show member pathways
10.95 ALDH2 ADH1C ADH1B ADH1A
12 10.86 DRD2 ANKK1
13 10.65 ALDH2 ADH1A
14 10.61 ADH1C ADH1B ADH1A
15
Show member pathways
10.46 SLC6A4 SLC6A3 DRD5 DRD4 DRD3 DRD2
16
Show member pathways
10.38 CHRNB4 CHRNA3

GO Terms for Substance Dependence

Cellular components related to Substance Dependence according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 11.16 ADH1A ADH1B ADH1C CHRNA3 CHRNA5 CHRNB4
2 plasma membrane GO:0005887 11.16 CHRNA3 CHRNA5 CHRNB4 CNR1 DRD2 DRD3
3 membrane GO:0016020 10.67 CHRNA3 CHRNA5 CHRNB4 CNR1 DRD2 DRD3
4 membrane GO:0016021 10.67 CHRNA3 CHRNA5 CHRNB4 CNR1 DRD2 DRD3
5 synapse GO:0045202 10.24 SLC6A4 GABRA2 DRD5 DRD3 DRD2 CNR1
6 membrane raft GO:0045121 10.22 CNR1 OPRD1 OPRM1 SLC6A3 SLC6A4
7 neuron projection GO:0043005 10.11 TPH1 SLC6A4 SLC6A3 OPRM1 OPRD1 GABRA2
8 GABA-ergic synapse GO:0098982 10.06 GABRA2 DRD3 DRD2 CNR1
9 axon terminus GO:0043679 10.02 SLC6A3 OPRD1 DRD2
10 dendrite membrane GO:0032590 9.95 OPRM1 OPRD1 GABRA2
11 acetylcholine-gated channel complex GO:0005892 9.91 CHRNA3 CHRNA5 CHRNB4
12 dopaminergic synapse GO:0098691 9.88 SLC6A3 DRD2 CHRNA5
13 presynaptic membrane GO:0042734 9.86 CNR1 DRD2 OPRD1 OPRM1 SLC6A3 SLC6A4
14 spine apparatus GO:0097444 9.81 OPRM1 OPRD1
15 obsolete integral component of postsynaptic membrane GO:0099055 9.62 SLC6A4 SLC6A3 OPRM1 DRD2
16 obsolete integral component of presynaptic membrane GO:0099056 9.43 CNR1 DRD2 OPRD1 OPRM1 SLC6A3 SLC6A4
17 postsynaptic membrane GO:0045211 9.4 SLC6A4 SLC6A3 OPRM1 OPRD1 GABRA2 DRD2

Biological processes related to Substance Dependence according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.5 CHRNA3 CHRNA5 CHRNB4 CNR1 DRD2 DRD3
2 chemical synaptic transmission GO:0007268 10.35 GABRA2 DRD5 DRD4 CHRNB4 CHRNA5 CHRNA3
3 regulation of membrane potential GO:0042391 10.27 CHRNA3 CHRNA5 CHRNB4 GABRA2
4 cellular calcium ion homeostasis GO:0006874 10.22 DRD5 DRD4 DRD3 DRD2
5 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 10.21 CNR1 DRD4 OPRD1 OPRM1
6 nervous system process GO:0050877 10.19 CHRNA3 CHRNA5 CHRNB4 GABRA2
7 locomotory behavior GO:0007626 10.19 CHRNA3 CHRNB4 DRD2 DRD3 SLC6A3
8 retinol metabolic process GO:0042572 10.18 ADH1C ADH1B ADH1A
9 social behavior GO:0035176 10.18 SLC6A4 DRD4 DRD3
10 neurotransmitter transport GO:0006836 10.17 SLC6A4 SLC6A3 GABRA2
11 response to amphetamine GO:0001975 10.15 DRD2 DRD4 DRD5
12 arachidonic acid secretion GO:0050482 10.13 DRD4 DRD3 DRD2
13 retinoic acid metabolic process GO:0042573 10.13 ADH1C ADH1B ADH1A
14 synaptic transmission, cholinergic GO:0007271 10.12 CHRNA3 CHRNA5 CHRNB4
15 negative regulation of protein secretion GO:0050709 10.11 DRD4 DRD3 DRD2
16 response to ethanol GO:0045471 10.1 SLC6A3 OPRM1 DRD3 DRD2 CNR1
17 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 10.09 DRD5 DRD3 DRD2
18 negative regulation of voltage-gated calcium channel activity GO:1901386 10.08 DRD4 DRD3 DRD2
19 dopamine metabolic process GO:0042417 10.08 DRD4 DRD3 DRD2
20 negative regulation of blood pressure GO:0045776 10.08 DRD5 DRD3 DRD2 CNR1
21 behavioral response to cocaine GO:0048148 10.07 DRD4 DRD3 DRD2
22 prepulse inhibition GO:0060134 10.04 DRD2 DRD3 SLC6A3
23 excitatory postsynaptic potential GO:0060079 10.03 OPRM1 GABRA2 DRD2 CHRNB4 CHRNA5 CHRNA3
24 negative regulation of synaptic transmission, glutamatergic GO:0051967 10.02 DRD3 DRD2
25 regulation of dopamine metabolic process GO:0042053 10.02 SLC6A3 DRD4
26 dopamine receptor signaling pathway GO:0007212 10.02 DRD5 DRD4 DRD2
27 behavioral response to ethanol GO:0048149 10.02 OPRM1 DRD4 DRD2
28 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 10.01 DRD5 DRD3
29 negative regulation of cytosolic calcium ion concentration GO:0051481 10.01 DRD3 DRD2
30 monoamine transport GO:0015844 10.01 SLC6A4 SLC6A3
31 adenohypophysis development GO:0021984 10.01 DRD2 SLC6A3
32 G protein-coupled opioid receptor signaling pathway GO:0038003 10.01 OPRD1 OPRM1
33 ethanol oxidation GO:0006069 10.01 ADH1C ADH1B ADH1A
34 hyaloid vascular plexus regression GO:1990384 10 DRD2 SLC6A3
35 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 10 DRD5 DRD3 DRD2
36 dopamine uptake involved in synaptic transmission GO:0051583 9.99 SLC6A3 DRD2
37 regulation of postsynaptic membrane potential GO:0060078 9.99 GABRA2 CHRNB4 CHRNA5
38 negative regulation of dopamine secretion GO:0033602 9.99 CNR1 DRD2
39 behavioral response to nicotine GO:0035095 9.99 CHRNB4 CHRNA5 CHRNA3
40 regulation of potassium ion transport GO:0043266 9.98 DRD2 DRD3
41 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.98 DRD2 DRD3
42 response to morphine GO:0043278 9.98 CNR1 DRD2 DRD3 OPRM1
43 synaptic transmission involved in micturition GO:0060084 9.97 CHRNB4 CHRNA3
44 response to nicotine GO:0035094 9.97 CHRNA5 CHRNB4 CNR1 DRD2 SLC6A3
45 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.96 DRD4 DRD2
46 acid secretion GO:0046717 9.96 DRD3 DRD2
47 regulation of locomotion involved in locomotory behavior GO:0090325 9.95 DRD3 DRD2
48 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.93 DRD4 DRD3 DRD2
49 synaptic transmission, dopaminergic GO:0001963 9.91 DRD5 DRD4 DRD3 DRD2
50 response to histamine GO:0034776 9.88 DRD4 DRD3 DRD2

Molecular functions related to Substance Dependence according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 10.37 OPRM1 OPRD1 DRD5 DRD4 DRD3 DRD2
2 transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential GO:1904315 10.03 CHRNA3 CHRNA5 CHRNB4 GABRA2
3 neurotransmitter receptor activity GO:0030594 10.02 CHRNA3 CHRNA5 CHRNB4 DRD4 GABRA2
4 ligand-gated monoatomic ion channel activity GO:0015276 10.01 CHRNA3 CHRNA5 CHRNB4
5 excitatory extracellular ligand-gated monoatomic ion channel activity GO:0005231 10.01 GABRA2 CHRNB4 CHRNA5 CHRNA3
6 NAD-retinol dehydrogenase activity GO:0004745 9.97 ADH1C ADH1B ADH1A
7 acetylcholine-gated monoatomic cation-selective channel activity GO:0022848 9.95 CHRNB4 CHRNA5 CHRNA3
8 acetylcholine receptor activity GO:0015464 9.93 CHRNB4 CHRNA5 CHRNA3
9 monoamine transmembrane transporter activity GO:0008504 9.88 SLC6A4 SLC6A3
10 alcohol dehydrogenase (NAD+) activity GO:0004022 9.87 ADH1C ADH1A
11 alcohol dehydrogenase activity, zinc-dependent GO:0004024 9.85 ADH1C ADH1B ADH1A
12 monoatomic ion channel activity GO:0005216 9.83 GABRA2 CHRNB4 CHRNA5 CHRNA3
13 G protein-coupled opioid receptor activity GO:0004985 9.72 OPRM1 OPRD1
14 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.63 DRD4 DRD3 DRD2
15 extracellular ligand-gated monoatomic ion channel activity GO:0005230 9.56 GABRA2 CHRNB4 CHRNA5 CHRNA3
16 dopamine binding GO:0035240 9.56 SLC6A3 DRD5 DRD4 DRD2
17 alcohol dehydrogenase [NAD(P)+] activity GO:0018455 9.51 ADH1C ADH1A
18 dopamine neurotransmitter receptor activity GO:0004952 9.1 DRD5 DRD4 DRD3 DRD2

Sources for Substance Dependence

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....